Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
88 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2016', provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Vaso-Occlusive Crisis Associated With Sickle Cell Disease - The report reviews pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutics and enlists all their major and minor projects - The report assesses Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Overview 7 Therapeutics Development 8 Pipeline Products for Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Overview 8 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics under Development by Companies 9 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Products under Development by Companies 13 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Companies Involved in Therapeutics Development 14 AstraZeneca Plc 14 Bristol-Myers Squibb Company 15 Complexa, Inc. 16 Dilaforette AB 17 Gilead Sciences, Inc. 18 Mast Therapeutics, Inc. 19 Pfizer Inc. 20 Seattle Genetics, Inc. 21 Selexys Pharmaceuticals Corporation 22 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 apixaban - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 CXA-10 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 NVX-508 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 regadenoson - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 rivipansel sodium - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 SelG-1 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 sevuparin sodium - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 SGD-2083 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 ticagrelor - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 vepoloxamer - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Recent Pipeline Updates 53 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects 79 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products 80 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Product Development Milestones 81 Featured News & Press Releases 81 Feb 22, 2016: Mast Therapeutics Completes Patient Enrollment In Pivotal Phase 3 "EPIC" Study For The Treatment Of Sickle Cell Crisis 81 Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel 82 Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology 82 Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel 83 Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015 84 Nov 06, 2014: GlycoMimetics Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting 84 Sep 26, 2014: GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel 84 Jul 01, 2014: GlycoMimetics Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Rivipansel (GMI-1070) 85 May 21, 2014: GlycoMimetics Receives $15 Million Payment from Pfizer in Connection with Planned Initiation of Phase 3 Trial 85 Sep 13, 2013: GlycoMimetics Announces EMA's Granting of Orphan Drug Status in European Union for GMI-1070 in Sickle Cell Disease 85 Appendix 87 Methodology 87 Coverage 87 Secondary Research 87 Primary Research 87 Expert Panel Validation 87 Contact Us 87 Disclaimer 88
List of Tables
Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by AstraZeneca Plc, H1 2016 14 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Company, H1 2016 15 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Complexa, Inc., H1 2016 16 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Dilaforette AB, H1 2016 17 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Gilead Sciences, Inc., H1 2016 18 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Mast Therapeutics, Inc., H1 2016 19 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Pfizer Inc., H1 2016 20 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Seattle Genetics, Inc., H1 2016 21 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline by Selexys Pharmaceuticals Corporation, H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics - Recent Pipeline Updates, H1 2016 53 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects, H1 2016 79 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products, H1 2016 80
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
